---oxo-isobutyl or isobutyryl---.

Page 13, line 14, delete "[prcduce]" and insert therefor ---product---.

Page 21, line 10, after "hydroxy-(11β, 16α)", insert

and 4.3 g (0.038 mol) of cyclohexane darbaldehyde are dissolved in it; subsequently tex.

Page 30, line 14, delete "arlucel 83" and insert therefor ---Arlacel 83---.

Page 31, line 28, delete "Dichlorotetrafluoromethane" and insert therefor --- Dichloro-tetrafluroethane---.

Page 32, line 11, delete "Mei" and insert therefor --- Meier---.

Page 35, Table II, for compounds 7, 8, 9, 13, 14, and 15, under the heading " $R_2$ ", insert:

Ca-

-

IN THE CLAIMS:

Please cancel claims 13 and 16.

Please add new claims 17-20 as follows:

to claim 1.

18. A method of treating inflammation while minimizing systemic glucocorticoid effect comprising administering an anti-inflammatorily effective amount of a compound according to claim 1.

Whiles.

23

A pharmaceutical composition having anti-inflammatory properties comprising as the active ingredient an effective amount of a compound according to claim 1 together with a pharmaceutically acceptable carrier.

20. A method for the treatment and control of inflammatory conditions in the mammalians, characterized by the topical administration of an effective dose of a compound according to claim 1.

## IN THE ABSTRACT:

Please replace the Abstract with the following: